Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q1

6523.TEDINET S100OZNU
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥81.5bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥340.5bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥80.9bn2021-04-01 → 2021-06-30Cons.Revenue IFRS
Operating income¥2.0bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥5.6bn2021-04-01 → 2021-06-30Cons.Operating profit loss IFRS
Profit before tax−¥6.3bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥3.0bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥14.1bn2021-04-01 → 2021-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥7.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥8.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥10.4bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥7.0bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥10.4bn2021-04-01 → 2021-06-30Cons.Profit loss IFRS
Total assets¥595.7bnat 2022-06-30Cons.Assets IFRS
Total assets¥591.3bnat 2022-03-31Cons.Assets IFRS
Total assets¥571.4bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥458.0bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥455.3bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥137.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥119.6bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥107.6bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥136.9bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥135.4bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥119.0bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥82.1bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥57.5bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.9bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥51.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥13.8bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥5.2bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥12.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥4.7bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥11.9bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥7.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥13.0bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-57.262022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-70.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥89.392021-04-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-57.262022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-70.782021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥86.312021-04-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio23.0%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio22.9%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio20.8%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30¥552m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-06-30¥552m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥6.7bn
jpcrp040300-q1r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-06-30¥26.5bn
jpcrp040300-q1r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-06-30¥26.5bn
jpcrp040300-q1r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-06-30¥23.4bn
jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-06-30¥23.4bn
jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-06-30¥31.1bn
jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-06-30¥31.1bn
jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.0bn
—segment totalrevenue2022-04-01 → 2022-06-30¥80.9bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥80.9bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥8.8bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30¥940m
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-06-30¥940m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥3.1bn
jpcrp040300-q1r_E36976-000Diabetes Managementreportable segmentrevenue2021-04-01 → 2021-06-30¥26.3bn
jpcrp040300-q1r_E36976-000Diabetes Managementreportable segmentrevenue external2021-04-01 → 2021-06-30¥26.3bn
jpcrp040300-q1r_E36976-000Diabetes Managementreportable segmentsegment profit2021-04-01 → 2021-06-30¥3.5bn
jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2021-04-01 → 2021-06-30¥21.9bn
jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2021-04-01 → 2021-06-30¥21.9bn
jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.7bn
jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segmentrevenue2021-04-01 → 2021-06-30¥31.8bn
jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segmentrevenue external2021-04-01 → 2021-06-30¥31.8bn
jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segmentsegment profit2021-04-01 → 2021-06-30¥3.6bn
—segment totalrevenue2021-04-01 → 2021-06-30¥80.0bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥80.0bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥8.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 810
ItemContextValueUnit
Revenue from external customers IFRSPrior1YTDDuration80909000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember26259000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember31763000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember21946000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember79968000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember940000000JPY
Revenue IFRSPrior1YTDDuration80909000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember3531000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember3574000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember1665000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember8771000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-3136000000JPY
Operating profit loss IFRSPrior1YTDDuration5634000000JPY
Finance income IFRSPrior1YTDDuration10630000000JPY
Finance costs IFRSPrior1YTDDuration2152000000JPY
Profit loss before tax IFRSPrior1YTDDuration14112000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember3451000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember2586000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember1639000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReportableSegmentsMember7677000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReconcilingItemsMember153000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration7831000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember2000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember2000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReportableSegmentsMember5000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Impairment losses pl IFRSPrior1YTDDuration5000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember26471000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember31067000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember23410000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember80949000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember552000000JPY
Revenue from external customers IFRSCurrentYTDDuration81502000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember26471000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember31067000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember23410000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember80949000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass